Biotech · Private company
Sylentis, S.A.
Track this companyFree. Adds Sylentis, S.A. to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- Tivanisiran sodium ophthalmic solutionPhase 3 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle ophthalmic solutionPhase 3 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- 1 drop of 0.375% SYL040012 (bamosiran)Phase 2 · Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- 1 drop of 0.5 % timolol maleatePhase 2 · Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- 1 drop of 0.750% SYL040012 (bamosiran)Phase 2 · Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- 1 drop of 1.125% SYL040012 (bamosiran)Phase 2 · Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- 1 drop of 1.5% SYL040012 (bamosiran)Phase 2 · Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Safety Study of Tivanisiran to Treat Dry EyePHASE3 · COMPLETED · started Mar 24, 2022ClinicalTrials.gov NCT05310422 · fetched Nov 12, 2026
- Tivanisiran for Dry Eye in Subjects With Sjögren's SyndromePHASE3 · COMPLETED · started May 25, 2021ClinicalTrials.gov NCT04819269 · fetched Nov 12, 2026
- SYL040012, Treatment for Open Angle GlaucomaPHASE2 · COMPLETED · started Oct 1, 2014ClinicalTrials.gov NCT02250612 · fetched Nov 12, 2026